Last reviewed · How we verify

Eledone Peptide — Competitive Intelligence Brief

Eledone Peptide (ELEDOISIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

phase 2 Neuromedin-K receptor Neuroscience Recombinant protein Live · refreshed every 30 min

Target snapshot

Eledone Peptide (ELEDOISIN). Eledoisin works by binding to the Neuromedin-K receptor, which is involved in various physiological processes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Eledone Peptide TARGET ELEDOISIN phase 2 Neuromedin-K receptor
Veozah FEZOLINETANT Astellas Pharma marketed Neurokinin 3 Receptor Antagonist [EPC] Neuromedin-K receptor 2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eledone Peptide — Competitive Intelligence Brief. https://druglandscape.com/ci/eledoisin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing